FROM 01 Apr, the eligibility criteria for access to Pfizer's Paxlovid (nirmatrelvir tablets and ritonavir tablets) on the PBS will be expanded to include people between 60-69 years of age with mild-to-moderate COVID-19 with one additional risk factor for developing severe disease.
Paxlovid is the one COVID-19 oral anti-viral medicine to receive this expanded PBS eligibility criteria.
Paxlovid is the first oral anti-viral of its kind for COVID-19, specifically designed to combat SARS- CoV-2.
The TGA granted provisional approval for Paxlovid based on positive results from the Phase 2/3 EPIC-HR trial, demonstrating 88% relative risk reduction in hospitalisation or death compared with placebo for patients who received treatment within five days from symptom onset, with demonstrated consistent efficacy across prespecified patient types and a range of comorbidities.
Paxlovid was well-tolerated in the EPIC-HR trial.
Learn more HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 31 Mar 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Mar 23
Warning: Undefined variable $o_shortcode_atts in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1263
Warning: Undefined variable $output in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1266
